Roche’s investigational flu drug, Xofluza® (baloxavir marboxil) has reduced the risk of complications in patients with flu in a late-stage clinical study. It is the first single-dose, oral drug being developed for flu with a novel mechanism of action in about the last 20 years.
AstraZeneca’s promising blood cancer drug, moxetumomab pasudotox has shown tumor shrinkage in 75 percent patients with hairy cell leukemia- a rare and chronic form of blood cancer.
Read about the most promising oncology drug candidates present in the pharmaceutical companies’ pipeline in 2018.
The potential drugs with novel mechanisms are in their late-stage of clinical development to treat diverse types of cancers.
Chinese biotech, Maxinovel Pharma’s immuno-oncology drug candidate- MAX-40279 received Orphan Drug designation from the US FDA for the treatment of ...
KEY POINTS Lorlatinib is a next-generation ALK/ROS1 tyrosine kinase inhibitor. Last year, lorlatinib had received Breakthrough Therapy designation from the ...
KEY POINTS YL Biologics announced the successful clinical outcome of YLB113- biosimilar version of Amgen’s blockbuster rheumatoid arthritis drug, Enbrel® ...